48,862
edits
Difference between revisions of "Prostate cancer"
Jump to navigation
Jump to search
→Sign out
| Line 356: | Line 356: | ||
#Gleason score including primary and secondary pattern, e.g. "Gleason score 3+4=7". | #Gleason score including primary and secondary pattern, e.g. "Gleason score 3+4=7". | ||
#Number of cores and number involved, e.g. "2/3 cores involved by cancer". | #Number of cores and number involved, e.g. "2/3 cores involved by cancer". | ||
#Percent area involved, i.e. how much of the core is cancer, e.g. "75% of specimen is tumour". | #Percent area involved, i.e. how much of the core is cancer, e.g. "75% of specimen is tumour". ‡ | ||
#Percent area involved that is Gleason pattern 4 or 5, e.g. "25% of the tumour is Gleason pattern 4 or 5". | #Percent area involved that is Gleason pattern 4 or 5, e.g. "25% of the tumour is Gleason pattern 4 or 5". | ||
#Presence of [[perineural invasion]]. | #Presence of [[perineural invasion]]. | ||
| Line 362: | Line 362: | ||
Notes: | Notes: | ||
*"Percent area involved" may seem like an odd thing to request 'cause it is sampling dependent, i.e. if the radiologist sticks the biopsy needle deeper into the lesion more of the core is positive, but urologists think it is important -- more important than perineural invasion.<ref>{{cite journal |author=Rubin MA, Bismar TA, Curtis S, Montie JE |title=Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients? |journal=Am. J. Surg. Pathol. |volume=28 |issue=7 |pages=946–52 |year=2004 |month=July |pmid=15223967 |doi= |url=}}</ref> | *‡ "Percent area involved" may seem like an odd thing to request 'cause it is sampling dependent, i.e. if the radiologist sticks the biopsy needle deeper into the lesion more of the core is positive, but urologists think it is important -- more important than perineural invasion.<ref name=pmid15223967>{{cite journal |author=Rubin MA, Bismar TA, Curtis S, Montie JE |title=Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients? |journal=Am. J. Surg. Pathol. |volume=28 |issue=7 |pages=946–52 |year=2004 |month=July |pmid=15223967 |doi= |url=}}</ref> | ||
**There is disagreement on how one should measure patchy cancer (cancer when there is interspersed normal). Epstein believes one should include the interspersed benign if the cancer is patchy, as the the groupings of tumour likely join out of the plane of section.<ref name=pmid21788055>{{Cite journal | last1 = Epstein | first1 = JI. | title = Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens. | journal = J Urol | volume = 186 | issue = 3 | pages = 790-7 | month = Sep | year = 2011 | doi = 10.1016/j.juro.2011.02.2695 | PMID = 21788055 }}</ref> | |||
**A review by Epstein on the topic of tumour volume suggests it does not have predictive value in multivariante analyses.<ref name=pmid21788055/> | |||
====Completely negative==== | ====Completely negative==== | ||